Regulation of cytochrome P-450 gene expression: studies with a cloned probe by Ravishankar, Honnavar & Padmanaban, Govindarajan
THE  JOURNAL OF BIOLOGICAL CAEMISTRY 
d i985 hy The American Society of Biological Chemists, tnc 
Vol. 260, No. 3, Issue of February 10, pp. 1588-1592,1985 
Printed in U.S.A. 
Regulation of Cytochrome P-450 Gene  Expression 
STUDIES  WITH A  CLONED  PROBE* 
(Received for publication, June 25, 1984) 
Honnavar  Ravishankar  and  Govindarajan  Padmanaban 
From the Department of Biochemistry, Indian  Institute of Science, Bangalore 560012, India 
A cDNA clone  for  cytochrome P-450e, a phenobar- 
bitone-inducible species in  rat liver, has  been  isolated 
and  characterized. With the  use  of this cloned  DNA,  an 
attempt  has  been  initiated to elucidate  the  factors reg- 
ulating  the  cytochrome P-450 gene  expression.  Inhib- 
itors  of  heme synthesis such as cobalt  chloride  and 3- 
amino-l,2,4-triazole block  the  induction  of cyto- 
chrome P-450e by  phenobarbitone  at  the level of  tran- 
scription. This is evident  from  the  decrease  in  the  rate 
of synthesis of  cytochrome P-450e, a  decrease  in  the 
levels of specific  translatable  messenger RNA, a de- 
crease  in  the  specific  cytoplasmic and  nuclear  messen- 
ger RNA contents,  and  nuclear  transcription  of  cyto- 
chrome P-450e gene, as revealed by  hybridization to 
the  cloned  probe,  under  these  conditions.  It i  proposed 
that  heme is a general  regulator of cytochrome P-450 
gene  expression at the level of  transcription,  whereas 
the  drug  or its metabolite  would  impart  the specificity 
needed  for  the  induction  of  a  particular  species. 
The cytochrome P-450 group of proteins plays an  important 
role in the metabolism of xenobiotics and is induced by a wide 
variety of chemicals (1, 2). They exhibit inducer specificity, 
and prototype chemicals induce different species of cyto- 
chrome P-450. For example, phenobarbitone induces cyto- 
chrome P-450b and e, whereas 3-methylcholanthrene induces 
cytochrome P-45Oc and d (3-5). Pre~enolone-l6~-carboni- 
trile induces yet another form of cytochrome P-450 (6) .  These 
are typical examples, and the induction of additional but 
drug-specific species of cytochrome P-450 are being reported 
(7 ,8) .  It  has been established that  the chemicals bring  about 
the de novo synthesis of specific cytochrome P-450 species 
resulting from the induction of specific messenger RNA spe- 
cies (9-12). Recent  studies have indicated that  the cytochrome 
P-450 group constitutes a multigene family, and prototype 
drugs activate specific genes at  the transcription level (13- 
16), although the mechanism of origin of the different mes- 
senger RNA species needs to be understood in greater detail. 
In an effort t.o identify the nature and site of action of 
factors regulating cytochrome P-450 gene expression in  rat 
liver, we have sought to examine the effects of a decrease in 
the heme pool which is modulated under  a  variety of condi- 
tions (17, 18). Heme, as a  prosthetic group, would naturally 
affect the  structural  and functional  properties of cytochrome 
P-450. But, we have also shown earlier that chemicals such 
as cobalt chloride, 3-amino-1,2,4-triazole, and thioacetamide, 
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which inhibit heme synthesis, mixed function oxidase activity, 
and depress cytochrome P-450 content estimated spectrally, 
bring  about  these effects by inhibiting the synthesis of apo- 
cytochrome P-450 (19-21). 
In  the present  study, we have constructed  a cDNA clone 
for  a cytochrome P-450 species induced by phenobarbitone, 
and using this probe, we have demonstrated that  the inhibi- 
tors of heme synthesis block the transcription of the cyto- 
chrome P-450 gene. 
EXPERIMENTAL PROCEDURES 
Treatment of Animals-Male rats of the Institute strain (90-100  g) 
were  given single injections of phenobarbitone (8 mg/100  g, intraper- 
itoneally), cobalt chloride (6 mg/100  g, s u ~ u t a n ~ u s l y ~ ,  and 3-amino- 
1,2,4-triazole (300 mg/100  g, intraperitoneally), where indicated. 
Construction of a cDNA  Clone for a Species of Cytochrome P-450 
Induced by Phenobarbitone-Poly(A)-containing RNA isolated from 
magnesium-precipitated polyribosomes (22) of phenobarbitone-in- 
jected rat livers was fractionated on 5-25% sucrose gradients. The 
16-18 S RNA (10 pg), coding for cytochrome P-450b/e as evident 
from reticulocyte cell-free translation experiments, was used for the 
preparation of single- and double-stranded cDNAs using reverse 
transcriptase  and DNA polymerase I (Klenow). The double-stranded 
cDNA  was cloned into Escherichia coli (C600) using pBR322 as vector 
and the GC tailing procedure. Tetracycline-resistant, ampicillin-sen- 
sitive clones were screened with [32P]~ingle-~tranded-cDNA prepared 
against purified cytochrome P-450b/e messenger RNA. Cytochrome 
P-450b/e messenger RNA was purified nearly 50-fold by immuno- 
binding of polyribosomes obtained from pbenobarbitone-injected rat 
liver with cytochrome P-450b/e antibodies and isolating the immu- 
nobound polyribosomes using protein A-Sepharose chromatography 
(23), followed by oligo(dT)-cellulose chromatography to isolate 
poly(A)-containing RNA. In  this procedure, 2000 Azm units of total 
polyribosomes yielded 2 pg  of RNA, enriched for cytochrome P-450b/ 
e messenger activity as revealed in reticulocyte translation experi- 
ments. The screening of a random population of 16 clones yielded 
two clones showing intense signals (Fig. 1). Clone 91 (marked by 
arrow in Fig, 1) was further analyzed along with a few other clones 
for fragment size, hybrid-selected messenger RNA translation, re- 
striction mapping, and partial sequencing of a few fragments by the 
Maxam-Gilbert procedure (24). Digestion of clone 91 DNA with PstI 
enzyme liberated a fragment, and  its mobility in 1.5% agarose gels 
indicated a size of 1100 base pairs (Fig. 2). Clone 91 DNA or  the 
insert was able to selectively hybrid-select an mRNA, which on 
translation in the reticulocyte cell-free system followed by immuno- 
binding to cytochrome P-45Ob/e antibodies and analysis of the im- 
munoprecipitate by  SDS’-gel analysis and fluorography was found to 
code for cytochrome P-450bfe species (Fig. 3). Restriction map of the 
fragment was carried out after end labeling with [ Y - ~ ~ P ] A T P  and
generating partials from unsymmetrically cut halrres (Fig. 4). Stand- 
ard protocols were  used in all the cloning manipulations and charac- 
terization of the recombinant DNA (25). For sequencing, the fragment 
was liberated with PstI, and the  PstI ends were  labeled with [Y-~’P] 
ATP, and  then  the fragment was cut with Hind111 to generate 460- 
and 620-base pair fragments. The two fragments were sequenced 
partially using 40-cm  gels. Multiple loadings facilitated the reading 
The abbreviations used are: SDS, sodium dodecyl sulfate; bp, base 
pairs; HEPES, 4-(Z-bydroxyethyl)-l-piperazineetbanesulfonic acid. 
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FIG. 1. Grunstein-Hogness colony hybridization with [s2P] 
cDNA prepared against purified cytochrome P-450b/e 
mRNA. Clone  91 indicated by arrow was taken for further  analysis. 
A B  C D 
FIG. 2. Size  of  the  insert   in  clone 91. The insert released on 
PstI digestion of DNA was analyzed on 1.5% agarose gel. A, uncut 
DNA; B, PstI-cut DNA; C, HindIII-cut DNA; D, size markers ob- 
tained with Hinf-cut  pBR DNA. 
of the sequences  partially.  A stretch of 30  nucleotides in  the 460-base 
pair  fragment  and a stretch of 175 nucleotides in  the 620-base pair 
fragment (Fig. 5) helped to  identify  clone  91  as a cytochrome  P-450e 
clone. 
Quantification of Messenger RNA Concentration for Cytochrome P- 
450b/e in  the Cytoplasm-Three procedures were employed  for this 
purpose. In  the  first procedure, microsomes were isolated from  the 
treated  animals,  and  protein  synthesis was carried  out  in vitro in  the 
A B C D E  
FIG. 3. Hybrid-selected mRNA translation. DNA-loaded fil- 
ters were hybridized to  poly(A)-containing RNA  isolated  from phen- 
obarbitone-treated  rat livers. The hybridized RNA was eluted, trans- 
lated,  treated with  cytochrome  P-450b/e antibody  and  the  immuno- 
precipitate was  analyzed on SDS-polyacrylamide gel electrophoresis 
(8% gels) and subjected to fluorography. A, clone 91 DNA, but 
translated  product  immunobound  to  albumin antibodies; B, clone 91 
DNA; C and D, DNAs from  clones not positive in  Grunstein-Hogness 
hybridization; E, pBR DNA. Arrow indicates position of cytochrome 
P-450b/e. 
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FIG. 4. Restriction map of clone 91. The  insert was released 
with  PstI  and end-labeled with [y3'P]ATP.  The end-labeled frag- 
ment was  digested  with HindIII  and  the two  labeled  fragments, 460 
and 620 bp, were used for restriction mapping by the  generation of 
partials. The orientation of the insert with respect to  the plasmid 
DNA was obtained  on  the basis of the size of the  fragments released 
with HindIII (Fig. 2). A, AuII; A,!,, AluI; B, BglII; HA, HaeIII; E, 
EcoRI; HD, HindIII; HF, HinfI; K, KpnI; M, MspI; T, TaqI. Thick 
line indicates pBR322  sequence, not  drawn  to scale. 
presence of 14C-labeled Chlorella protein hydrolysate and  other com- 
ponents  (19).  The  mixture was incubated a t  37 "C for 20 min  and 
then processed by immunoprecipitation  and SDS-polyacrylamide gel 
electrophoresis  using 8% gels. The cytochrome P-450b/e band was 
sliced out, digested  with H202, and radioactivity  measured  using 0.5% 
(w/v)  in  Triton X-lOO/toluene (1:2) as  mixture (19). 
In  the second  procedure, 8 pg of poly(A)-containing  RNA isolated 
from the livers of rats given the  different  treatments was translated 
in  the reticulocyte  cell-free system  (26)  in a total volume of 100 r l  in 
presence of [35S]mzthionine. The  translated  products were immuno- 
bound to cytochrome P-450b/e antibodies. The antigen-antibody 
complex  was  isolated using Staphylococcus aureus cells and analyzed 
by SDS-polyacrylamide gel electrophoresis (8% gels) and fluorogra- 
phy. 
In  the  last procedure, 10 pg of poly(A)-containing  RNA obtained 
from rat livers given the different treatments was fractionated on 
agarose-urea gels (1.5%) and analyzed by Northern blot  hybridization 
with  nick-translated [32P]cDNA (lo6 cpm/ml) from  clone 91 (27, 28). 
Quantification of Messenger RNA Concentration for Cytochrome P- 
450b/e in the Nucleus-The procedure described by Guertin et al. 
(29) was followed without  any modification. Briefly, RNA  was first 
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FIG. 5. Partial sequencing of restriction fragments. The ex- 
perimental  details  are given in text. A, a sequence of 30 nucleotides 
in the 460-bp fragment. B ,  a sequence of 175 nucleotides in the 620- 
bp fragment. The underlined residues in cytochrome P-45Oe are 
replaced by the ones indicated above in cytochrome P-450b. 
isolated from the nuclei of control and treated animals. The nuclei 
were lysed in presence of 2% (w/v) SDS and 7 M urea followed by 
phenol/chloroform extraction and ethanol precipitation. The pellet 
was treated with DNase I and proteinase K followed by phenol/ 
chloroform extraction and ethanol precipitation. The final prepara- 
tion was reprecipitated in presence of 2.5 M LiCl.  RNA (10 pg) was 
loaded onto nitrocellulose filters in 20 X SSC, and the hybridization 
medium contained nick-translated [32P]cDNA ( lo6 cpm/ml) from 
clone 91. 
Cell-free Nuclear Transcription-This was also carried out essen- 
tially as described by Guertin  et al. (29). The reaction mixture in a 
total volume of  200 pl contained HEPES  (pH 7.6), 20  mM; NaCl, 150 
mM; magnesium acetate,  5 mM; MnCI2, 1 mM; EDTA, 0.1 mM; 
dithiothreitol, 2 mM; ATP, GTP, and CTP, 0.4 mM each [ U - ~ ~ P ]  
UTP, 4 p ~ ;  placental RNase inhibitor, 500 units/ml;  creatine phos- 
phate, 2 mM; creatine phosphokinase, 3  units/ml; glycerol, 16% (v/ 
v), and nuclei equivalent to 200  pg  of  DNA. The incubation was at  
25 "C for 45 min. Labeled RNA was isolated after DNase I and 
proteinase K treatments. The RNA preparation was also washed with 
5% (w/v) trichloroacetic acid. The final pellet was dissolved in 10 
mM Tris, 0.1% SDS  (pH 8.0). Clone 91 DNA (40 pg)  was loaded onto 
nitrocellulose discs (30), and hybridization with the RNA transcribed 
in vitro (3.5 X 10' cpm) was carried out as described by Guertin  et al. 
(29). After incubation, the filters were washed, dried, and radioactivity 
directly measured using 0.5% (w/v) 2,5-diphenyloxazole in toluene as 
mixture. 
Other Procedures-Purification of cytochrome P-450 from pheno- 
barbitone-treated rats, preparation and purification of antibodies 
conditions for immunoprecipitation, and analysis by SDS-polyacryl- 
amide gel electrophoresis have all been described in previous publi- 
cations (9, 10, 20, 21). 
RESULTS 
We have established that clone 91  is for a species of cyto- 
chrome P-450 induced by phenobarbitone on the basis of 
Grunstein-Hogness hybridization (Fig. 1) and hybrid-selected 
messenger RNA translation (Fig. 3). It  is known that cyto- 
chrome P-450b and e are highly homologous at  the protein 
and messenger RNA  levels (4,16,31,32).  The restriction map 
of the 1100-bp insert  in clone 91 agrees very  closely with the 
sequence data provided for R17 which has been characterized 
to be a cytochrome P-450e clone (31). Some of the specific 
identifying features for cytochrome P-450e clone obtained in 
the present study are (a) loss of MspI site at 215 bp, but 
appearance of a new MspI  site a t  123 bp. The sequence of 30 
nucleotides obtained in  this region demonstrates the substi- 
tution of an A residue present  in cytochrome P-450b by a G 
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residue in cytochrome P-45Oe such that  the MspI  site GGCC 
is created. In addition, a new HaeIII  site at 218 bp resulting 
in a unique HaeIII-BglII fragment of about 100 bp also agrees 
with that of the sequence reported for the R17  clone. (b) The 
sequence of 175 nucleotides obtained at  the 3'-end for clone 
91 is identical to  that reported for R17 and shows five single 
base substitutions compared to cytochrome P-450b. The ori- 
entation of the  insert  in clone 91 with respect to  the plasmid 
sequences is as depicted in Fig.  5. 
The ability of microsomes isolated from control and drug- 
treated  animals to synthesize cytochrome P-450b/e in uitro 
as assessed by immunoprecipitation, SDS-gel analysis, and 
the radioactivity in  the protein  band  is given in  Table I. As is 
now well established (9-12), phenobarbitone treatment  en- 
hances cytochrome P-450b/e synthesis. The interesting fea- 
ture is that CoClz  given along with phenobarbitone or 90 min 
after the drug administration is able to inhibit cytochrome P- 
450b/e synthesis. In  the  latter case, the inhibitory effect of 
C0C12 is less than in the former case. 3-Amino-1,2,4-triazole 
also inhibits the phenobarbitone-mediated increase in cyto- 
chrome P-450b/e synthesis, but only when  given in sufficient 
time before phenobarbitone. 
The results obtained in the homologous cell-free system 
can be confirmed by translating  the RNA isolated from the 
treated livers in  the reticulocyte lysate cell-free system (Fig. 
6). It is once again clear that CoClz and 3-amino-1,2,4-triazole 
are effective in suppressing the phenobarbitone-mediated in- 
crease in the translatable activity of cytochrome P-450b/e 
messenger RNA. CoC12 is effective, but predictably to a lesser 
extent, even when administered 12 h after phenobarbitone 
treatment.  The ability of CoCl2 to block cytochrome P-450 
synthesis and  the translatability of its messenger  RNA even 
when administered after phenobarbitone treatment, albeit 
partially, would indicate the rapid turnover of the messenger, 
requiring continued synthesis to maintain  its level. 
Northern blot analysis of the polysomal poly(A)-containing 
RNA isolated from control and  drug-treated  animals using 
nick-translated clone 91  is presented in Fig. 7. The content 
of cytochrome P-450b/e mRNA increases strikingly after 
phenobarbitone treatment, and CoClZ treatment effectively 
blocks this increase. The size of the messenger estimated from 
the mobility of markers  is  around 1950 f 80 nucleotides in 
all treatment conditions. 
The quantitation of cytochrome P-450b/e messenger pre- 
TABLE I 
Synthesis of cytochrome P-450ble by microsomes  isolated from drug- 
treated animals 
The animals were killed 6  h  after phenobarbitone administration, 
and protein synthesis was carried out with isolated microsomes. After 
in vitro protein synthesis  in presence of "C-labeled  Chlorella protein 
hydrolysate, the microsomes  were solubilized and treated with cyto- 
chrome P-450b/e antibodies. The immunoprecipitates were analyzed 
on SDS-gels, and  the cytochrome P-450 band was cut  out, digested 
with H202, and radioactivity measured. The amount of total protein 
radioactivity taken for immunoprecipitation was 1.2 X 106 cpm in 
each case. 
Treatment Radioactivity in cytochrome P-450 
Control 
Phenobarbitone 
Phenobarbitone + CoC12" 
Phenobarbitone + CoC1; 
Phenobarbitone + 3-amino- 
1.2.4-triazole 
cpm 
138 
708 
152 
258 
145 
a CoC12 administered at  the same time as phenobarbitone. 
* CoC12 administered 90 min after phenobarbitone. 
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FIG. 6. Effect of CoCI2 on phenobarbitone-mediated in- 
crease in the translatable levels of cytochrome P-450b/e 
mRNA. I: A, control; B, phenobarbitone  treatment (6 h); C, pheno- 
barbitone + CoC12 treatment (6 h); D, phenobarbitone (6 h) + 3- 
amino-1,2,4-triazole (10 h) treatment. II: A, phenobarbitone treat- 
ment (12 h); B, phenobarbitone  (12  h) + CoC12 (2 h)  treatments; C, 
control. Arrow indicates  the position of cytochrome P-450b/e. 
cursor  in  the nucleus  by dot-blot hybridization is  presented 
in Fig. 8. Discernible hybridization can only be seen after 
phenobarbitone  treatment,  indicating  an  increase  in  the con- 
tent of rapidly turning over  pools of the  cytochrome P-450b/ 
e  messenger precursors  under  these conditions.  Once  again, 
CoC12 and 3-amino-l,2,4-triazole treatments effectively block 
the  phenobarbitone effect. 
Finally, data  on in uitro transcription  with nuclei  isolated 
from control  and  drug-treated  animals  are  presented  in  Table 
11. It  is  clear  that  cytochrome P-450b/e transcripts can be 
detected in significant quantity soon after phenobarbitone 
treatment. CoC12 and 3-amino-1,2,4-triazole treatments  are 
a t  least  65% effective in blocking the  action of phenobarbi- 
tone, in this runoff transcription assay where the chains 
initiated in  uiuo are completed. This  is probably a minimal 
estimate  since  phenobarbitone  induces cytochrome  P-450b/e 
gene  expression  very  rapidly, and  the  depletion of the  heme 
pool in  uiuo at  the  time  period  examined may not  have been 
adequate to completely block initiation of transcription. Al- 
ternatively, inhibitors of heme synthesis may also have an 
additional effect on cytochrome P-450 synthesis a t  post- 
transcriptional  sites. I t  may  be pointed  out  that  none of the 
treatments led to a significant  change  in  the  total  transcrip- 
tion  rates  measured  with isolated nuclei. 
DISCUSSION 
Heme  is  implicated  in  regulating  the levels of hemoproteins 
and  enzymes involved in  heme metabolism and influences a 
wide variety of molecular  processes (33-35). Earlier  studies  in 
this  laboratory (19-21) as well as the  results  obtained  in  this 
study clearly establish  that  inhibitors of heme  synthesis mod- 
ulate  the  expression of the  cytochrome  P-450 gene at   the  level 
of transcription.  This we have  established  on  the  basis of the 
quantitation of the  cytochrome P-450b/e  species by SDS-gel 
electrophoresis  and  radial immunodiffusion, measurements of 
the rate of cytochrome P-450b/e synthesis in homologous 
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FIG. 7. Northern blot analysis of cytochrome P-450e mRNA 
under conditions of phenobarbitone and phenobarbitone + 
CoClz treatments. Poly(A)-containing RNA  was  isolated  from rat 
livers given the  drug  treatment for 6 h. 10 pg of RNA was analyzed 
on urea-agarose gels (1.5%), blotted into nitrocellulose filters, and 
then hybridized to  nick-translated clone 91 DNA insert. A, control; 
B, phenobarbitone  treatment; C, phenobarbitone + CoC12 treatment. 
The position of size markers  and cytochrome  P-450b/e is indicated 
by arrows. 
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FIG. 8. Dot-blot hybridization of nuclear RNA. Nuclear  RNA 
was  isolated  4  h after  the  drug  treatments  and 10 pg was used for dot- 
blot hybridization  with nick-translated clone  91 DNA insert. A, 
control; B, phenobarbitone treatment; C, phenobarbitone + CoC12 
treatment; D, phenobarbitone + 3-amino-1,2-4-triazole treatment. 
cell-free systems, and the translatability of the messenger 
RNA  in heterologous cell-free systems, quantitation of cyto- 
chrome P-450b/e  messenger  RNA in  the cytoplasm and  the 
transcripts in the nucleus, and finally measurement of the 
rate of cytochrome  P-450b/e gene transcription with  isolated 
nuclei in  uitro. It  has  not, however, been possible to counteract 
the effect of the  inhibitors of heme synthesis by the  admin- 
istration of exogenous hematin. We feel that  this  is only a 
case of the accessibility of the regulatory site to exogenous 
heme, in view of its known  nonspecific interaction with pro- 
teins and complications arising out of the time-dependent 
regulation of the endogenous heme pool by exogenous heme. 
The  mechanism of translocation of a  regulatory pool of heme 
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TABLE I1 10. Kumar, A., and  Padmanaban, G. (1980) J.  Biol. Chem. 255,522- 
Transcription with nuclei isolated from drug-treated animals 525 
The animals were killed 4 h after phenobarbitone  administration 11. Adesnik, M., Bar-Nun, s.7 Maschio, F.9 Zunich, M., LiPPman, A., 
and nuclei isolated. Labeled RNA (3.5 X lo5 cpm) transcribed in vitro 12, Morville, A, L., Thomas, p., Levin, w., Reik, L., Ryan, D. E., and  Bard,  E. (1981) J.  Biol. Chem. 256, 10340-10345 
was hybridized to  filters containing clone 91 DNA insert, and the 
radioactivity of the hybridized RNA was measured. 3906 
Raphael, C., and Adesnik, M. (1983) J.  Biol. Chem. 258,3901- 
Treatment RNA hybridized 13. Hardwick, J .  P., Gonzaiez, F. J.,  and  Kasper, C. B. (1983) J.  Biol. 
Chem. 258,8081-8085 
14. Nebert, D. W., Eisen,  H.  J.,  and  Hankinson, 0. (1984) Biochem. 
Pharmacol. 33, 917-924 
15. Nebert,  D. W., Negishi, M., Lang, M. A., Hjelmeland, L. M., and 
Eisen, H. J. (1982) Adu. Genet. 21, 1-52 
16. Atchison, M., and Adesnik, M. (1983) J. Biol. Chem. 258,11285- 
11295 
17. Granick, S., and Beale, S. (1978) Adu. Enzymol. 46, 33-203 
into  the nucleus remains  to  be worked out.  We would like to 18. De  Matteis,  F. (1978) in Handbook of Experimental Pharmacology 
propose that the expression of cytochrome P-450 genes is 
(De Matteis, F., and Aldridge, W. N., eds), Vol. 44, pp. 129- 
155, Springer-Verlag/Berlin, Heidelberg, New York 
governed at  the level of transcription by at least two param- 19. Bhat, K. S., and Padmanaban, G. (1978) FEBS Lett. 89, 337- 
eters. One is the inducing chemical or its metabolite and the 20, Ravishankar, H,, and Padmanaban, G. (1983) Arch, Biochem, 340 
other  one is heme. Heme may function  as a  general  regulatory 
molecule governing the synthesis of all cytochrome P-450 21. Sathyabhama, S., and Padmanaban, G. (1984) Biochem. J. 218, 
Biophys. 225, 16-24 
species, whereas  the  drug may impart  the specificity  needed 371-377 
for the  induction of a particular species. It would be  interest- ig: ki:z,,R;,"d ~ ~ ~ ~ ~ ~ ~ " L r " ~ f ' 1 1 ~ ~ ~ ) 3 ~ ~ ~ ~ ~ ~ t 1 ,  Acad. sei, ing to  examine  the  sites of interaction of the  drug  and heme U. S. A. 79, 4015-4019 
at  the level of chromatin  in  this regard. 24. Maxam, A. M., and Gilbert, W. (1980) Methods Enzymol. 65, 
499-560 
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